<p>GW&amp;K Investment Management LLC 在最近向证券交易委员会的披露中表示，在第三季度将其在 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 免费报告) 的持股增加了 9.1%。该机构投资者在本季度购买了额外的 95,858 股后，持有该公司 1,144,330 股股票。GW&amp;K Investment Management LLC 在最近的报告期末持有的 Phathom Pharmaceuticals 的股份约占 1.61%，价值 13,469,000 美元。</p>
<p>其他一些对冲基金和机构投资者最近也买卖了该公司的股票。Frazier Life Sciences Management L.P. 在第二季度将其在 Phathom Pharmaceuticals 的持股增加了 23.3%。Frazier Life Sciences Management L.P. 目前持有 12,466,489 股该公司的股票，价值 119,554,000 美元，此前在上个季度购买了额外的 2,357,210 股。Invesco Ltd. 在第二季度将其在 Phathom Pharmaceuticals 的股份增加了 13.4%。Invesco Ltd. 目前持有 4,140,072 股该公司的股票，价值 39,703,000 美元，此前在上个季度购买了额外的 489,260 股。Vanguard Group Inc. 在第三季度将其在 Phathom Pharmaceuticals 的持股增加了 15.4%。Vanguard Group Inc. 目前持有 3,215,572 股该公司的股票，价值 37,847,000 美元，此前在上个季度购买了额外的 428,261 股。683 Capital Management LLC 在第二季度将其在 Phathom Pharmaceuticals 的持股增加了 45.7%。683 Capital Management LLC 目前持有 2,105,000 股该公司的股票，价值 20,187,000 美元，此前在上个季度购买了额外的 660,000 股。最后，Geode Capital Management LLC 在第二季度将其在 Phathom Pharmaceuticals 的股份增加了 5.3%。Geode Capital Management LLC 目前持有 1,069,927 股该公司的股票，价值 10,263,000 美元，此前在此期间购买了额外的 53,504 股。机构投资者持有该公司 99.01% 的股份。</p>
<h2>Phathom Pharmaceuticals 股票下跌 0.7%</h2>
<p>NASDAQ:PHAT 的股票周五开盘价为 10.67 美元。Phathom Pharmaceuticals, Inc. 的 12 个月最低价为 2.21 美元，最高价为 18.31 美元。该股票的 50 日移动平均线为 13.62 美元，200 日移动平均线为 13.50 美元。该公司的市值为 8.408 亿美元，市盈率为 -3.49，贝塔值为 0.51。</p>
<p>Phathom Pharmaceuticals (NASDAQ:PHAT - 获取免费报告) 最近在 2 月 26 日星期四公布了季度财报。该公司报告本季度每股收益为（0.08）美元，超出分析师的共识预期（0.09）美元 0.01 美元。该公司的季度收入为 5758 万美元，而共识预期为 5744 万美元。股票研究分析师预计 Phathom Pharmaceuticals, Inc. 在当前财政年度将发布 -4.78 的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>PHAT 已成为几份分析师报告的主题。Stifel Nicolaus 在 2 月 26 日星期四的研究报告中将 Phathom Pharmaceuticals 的目标价设定为 28.00 美元。Guggenheim 在 2 月 27 日星期五的研究报告中将 Phathom Pharmaceuticals 的目标价从 20.00 美元上调至 25.00 美元，并给予该股票 &#34;买入&#34; 评级。Raymond James Financial 在 12 月 11 日星期四对 Phathom Pharmaceuticals 开始覆盖。他们对该股票给予了 &#34;强力买入&#34; 评级，并设定了 28.00 美元的目标价。Weiss Ratings 在 1 月 22 日星期四的报告中重申了对 Phathom Pharmaceuticals 股票的 &#34;卖出（d-）&#34; 评级。最后，Cantor Fitzgerald 在 1 月 14 日星期三的研究报告中重申了对 Phathom Pharmaceuticals 股票的 &#34;增持&#34; 评级。一位投资分析师对该股票给予了强力买入评级，五位给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 &#34;适度买入&#34;，共识目标价为 22.25 美元。</p>
<p><strong>查看我们关于 PHAT 的最新股票报告</strong></p>
<h2>关于 Phathom Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>Phathom Pharmaceuticals 是一家临床阶段的生物制药公司，专注于开发和商业化针对胃肠道（GI）疾病的新型治疗方法。该公司的核心使命是通过利用创新的作用机制来改善患者的治疗效果，从而解决严重的胃肠道疾病。Phathom 的研发工作集中在如幽门螺杆菌感染、侵蚀性食管炎、胃轻瘫及其他功能性胃肠道疾病等存在重大未满足医疗需求的病症上。</p>
<p>该公司的主要资产是 vonoprazan，一种钾竞争性酸阻滞剂（P-CAB），已在美国获得使用许可。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Phathom Pharmaceuticals</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>埃隆·马斯克已经让我成为一个 “富有的人”</li>
</ul>
<p><strong>想看看其他对冲基金持有的 PHAT 吗？</strong> 访问 HoldingsChannel.com 获取 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEhBVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEhBVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Phathom Pharmaceuticals 吗？</h2>
<p>在你考虑投资 Phathom Pharmaceuticals 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Phathom Pharmaceuticals 并不在名单上。</p>
<p>虽然 Phathom Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做空 - Direxion

动态生物技术与基因组 ETF - Invesco

PHAT

<p>GW&K Investment Management LLC 在第三季度将其在 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) 的持股增加了 9.1%，目前持有 1,144,330 股，价值约为 1347 万美元。其他机构投资者也增加了他们的持股，其中 Frazier Life Sciences Management L.P. 增加了 23.3%。Phathom 的股票目前下跌 0.7%，交易价格为 10.67 美元，市值为 8.408 亿美元。分析师的评级意见不一，普遍目标价为 22.25 美元。Phathom 专注于开发胃肠疾病的治疗方案，其主要资产为 vonoprazan</p>

<p>GW&amp;K Investment Management LLC boosted its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 9.1% during the 3rd quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor owned 1,144,330 shares of the company's stock after buying an additional 95,858 shares during the quarter. GW&amp;K Investment Management LLC owned approximately 1.61% of Phathom Pharmaceuticals worth $13,469,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>GW&amp;K Investment Management LLC 在最近向证券交易委员会的披露中表示，在第三季度将其在 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 免费报告) 的持股增加了 9.1%。该机构投资者在本季度购买了额外的 95,858 股后，持有该公司 1,144,330 股股票。GW&amp;K Investment Management LLC 在最近的报告期末持有的 Phathom Pharmaceuticals 的股份约占 1.61%，价值 13,469,000 美元。</p>
</div><p>A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Frazier Life Sciences Management L.P. increased its holdings in Phathom Pharmaceuticals by 23.3% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 12,466,489 shares of the company's stock worth $119,554,000 after purchasing an additional 2,357,210 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Phathom Pharmaceuticals by 13.4% during the second quarter. Invesco Ltd. now owns 4,140,072 shares of the company's stock valued at $39,703,000 after purchasing an additional 489,260 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Phathom Pharmaceuticals by 15.4% during the third quarter. Vanguard Group Inc. now owns 3,215,572 shares of the company's stock worth $37,847,000 after purchasing an additional 428,261 shares during the last quarter. 683 Capital Management LLC grew its holdings in shares of Phathom Pharmaceuticals by 45.7% during the second quarter. 683 Capital Management LLC now owns 2,105,000 shares of the company's stock worth $20,187,000 after purchasing an additional 660,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Phathom Pharmaceuticals by 5.3% in the second quarter. Geode Capital Management LLC now owns 1,069,927 shares of the company's stock valued at $10,263,000 after buying an additional 53,504 shares during the period. Institutional investors own 99.01% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也买卖了该公司的股票。Frazier Life Sciences Management L.P. 在第二季度将其在 Phathom Pharmaceuticals 的持股增加了 23.3%。Frazier Life Sciences Management L.P. 目前持有 12,466,489 股该公司的股票，价值 119,554,000 美元，此前在上个季度购买了额外的 2,357,210 股。Invesco Ltd. 在第二季度将其在 Phathom Pharmaceuticals 的股份增加了 13.4%。Invesco Ltd. 目前持有 4,140,072 股该公司的股票，价值 39,703,000 美元，此前在上个季度购买了额外的 489,260 股。Vanguard Group Inc. 在第三季度将其在 Phathom Pharmaceuticals 的持股增加了 15.4%。Vanguard Group Inc. 目前持有 3,215,572 股该公司的股票，价值 37,847,000 美元，此前在上个季度购买了额外的 428,261 股。683 Capital Management LLC 在第二季度将其在 Phathom Pharmaceuticals 的持股增加了 45.7%。683 Capital Management LLC 目前持有 2,105,000 股该公司的股票，价值 20,187,000 美元，此前在上个季度购买了额外的 660,000 股。最后，Geode Capital Management LLC 在第二季度将其在 Phathom Pharmaceuticals 的股份增加了 5.3%。Geode Capital Management LLC 目前持有 1,069,927 股该公司的股票，价值 10,263,000 美元，此前在此期间购买了额外的 53,504 股。机构投资者持有该公司 99.01% 的股份。</p>
</div><h2>Phathom Pharmaceuticals Stock Down 0.7%</h2>
<div class="lb-trans"><h2>Phathom Pharmaceuticals 股票下跌 0.7%</h2>
</div><p>Shares of NASDAQ:PHAT opened at $10.67 on Friday. Phathom Pharmaceuticals, Inc. has a twelve month low of $2.21 and a twelve month high of $18.31. The stock's 50 day moving average is $13.62 and its 200-day moving average is $13.50. The firm has a market capitalization of $840.80 million, a price-to-earnings ratio of -3.49 and a beta of 0.51.</p>
<div class="lb-trans"><p>NASDAQ:PHAT 的股票周五开盘价为 10.67 美元。Phathom Pharmaceuticals, Inc. 的 12 个月最低价为 2.21 美元，最高价为 18.31 美元。该股票的 50 日移动平均线为 13.62 美元，200 日移动平均线为 13.50 美元。该公司的市值为 8.408 亿美元，市盈率为 -3.49，贝塔值为 0.51。</p>
</div><p>Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. The business had revenue of $57.58 million for the quarter, compared to the consensus estimate of $57.44 million. Equities research analysts anticipate that Phathom Pharmaceuticals, Inc. will post -4.78 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals (NASDAQ:PHAT - 获取免费报告) 最近在 2 月 26 日星期四公布了季度财报。该公司报告本季度每股收益为（0.08）美元，超出分析师的共识预期（0.09）美元 0.01 美元。该公司的季度收入为 5758 万美元，而共识预期为 5744 万美元。股票研究分析师预计 Phathom Pharmaceuticals, Inc. 在当前财政年度将发布 -4.78 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>PHAT has been the subject of several analyst reports. Stifel Nicolaus set a $28.00 target price on Phathom Pharmaceuticals in a research report on Thursday, February 26th. Guggenheim raised their price objective on Phathom Pharmaceuticals from $20.00 to $25.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, February 27th. Raymond James Financial assumed coverage on Phathom Pharmaceuticals in a report on Thursday, December 11th. They issued a &#34;strong-buy&#34; rating and a $28.00 target price on the stock. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Phathom Pharmaceuticals in a report on Thursday, January 22nd. Finally, Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $22.25.</p>
<div class="lb-trans"><p>PHAT 已成为几份分析师报告的主题。Stifel Nicolaus 在 2 月 26 日星期四的研究报告中将 Phathom Pharmaceuticals 的目标价设定为 28.00 美元。Guggenheim 在 2 月 27 日星期五的研究报告中将 Phathom Pharmaceuticals 的目标价从 20.00 美元上调至 25.00 美元，并给予该股票 &#34;买入&#34; 评级。Raymond James Financial 在 12 月 11 日星期四对 Phathom Pharmaceuticals 开始覆盖。他们对该股票给予了 &#34;强力买入&#34; 评级，并设定了 28.00 美元的目标价。Weiss Ratings 在 1 月 22 日星期四的报告中重申了对 Phathom Pharmaceuticals 股票的 &#34;卖出（d-）&#34; 评级。最后，Cantor Fitzgerald 在 1 月 14 日星期三的研究报告中重申了对 Phathom Pharmaceuticals 股票的 &#34;增持&#34; 评级。一位投资分析师对该股票给予了强力买入评级，五位给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 &#34;适度买入&#34;，共识目标价为 22.25 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on PHAT</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 PHAT 的最新股票报告</strong></p>
</div><h2>About Phathom Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Phathom Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company's core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom's research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals 是一家临床阶段的生物制药公司，专注于开发和商业化针对胃肠道（GI）疾病的新型治疗方法。该公司的核心使命是通过利用创新的作用机制来改善患者的治疗效果，从而解决严重的胃肠道疾病。Phathom 的研发工作集中在如幽门螺杆菌感染、侵蚀性食管炎、胃轻瘫及其他功能性胃肠道疾病等存在重大未满足医疗需求的病症上。</p>
</div><p>The company's lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.</p>
<div class="lb-trans"><p>该公司的主要资产是 vonoprazan，一种钾竞争性酸阻滞剂（P-CAB），已在美国获得使用许可。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Phathom Pharmaceuticals</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>Elon Musk already made me a “wealthy man”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Phathom Pharmaceuticals</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>埃隆·马斯克已经让我成为一个 “富有的人”</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PHAT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 PHAT 吗？</strong> 访问 HoldingsChannel.com 获取 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEhBVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PHAT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Phathom Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Phathom Pharmaceuticals 吗？</h2>
</div><p>Before you consider Phathom Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Phathom Pharmaceuticals 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Phathom Pharmaceuticals 并不在名单上。</p>
</div><p>While Phathom Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Phathom Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

GW&K Investment Management LLC Has $13.47 Million Stock Position in Phathom Pharmaceuticals, Inc. $PHAT

Market Beat

Phathom Pharmaceuticals

GW&K Investment Management LLC 在 Phathom Pharmaceuticals, Inc. $PHAT 持有价值 1347 万美元的股票头寸